Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics, Inc. (BNGO) and Hamilton announced the commercial availability of the Long String VANTAGE, an automated system for high throughput isolation of ultra-high molecular weight (UHMW) DNA. This system improves the efficiency of optical genome mapping (OGM) using human blood samples, allowing labs to process up to 24 samples in an eight-hour workday. Shipping is expected to begin in Q1 2023 as part of ongoing collaboration for clinical applications. The development aims to enhance genomic analysis accuracy, reducing hands-on time and improving result consistency.

Bionano Genomics hosted its first "Meet the User" event on October 24, 2022, at its new CLIA-certified laboratories in San Diego. The event gathered over 50 participants from multiple countries, focusing on optical genome mapping (OGM). Attendees experienced hands-on demonstrations of the Saphyr system and NxClinical software, along with educational sessions on data analysis for rare diseases. Bionano aims to enhance OGM adoption and provided insights into their product roadmap, showcasing the growing interest in genomic solutions.

Bionano Genomics (BNGO) announced its participation in the ASHG Annual Meeting 2022, showcasing its optical genome mapping (OGM) technology. Key presentations include a multi-site clinical study of OGM's application in postnatal genetic disorders and significant advancements in molecular cytogenetics. The conference will feature a record 24 scientific presentations on OGM's utility in genetic disease research. Notably, Bionano will present new data from its partnership with Hamilton on the Long String VANTAGE system, enhancing ultra-high molecular weight DNA extraction processes.

Bionano Genomics (BNGO) announced a peer-reviewed study validating optical genome mapping (OGM) for noninvasive prenatal testing (NIPT) results. The research, conducted at Hangzhou Maternity and Child Care Hospital, found OGM effectively identifies complex chromosomal rearrangements (CCR) tied to recurrent pregnancy loss, with 70% of CCR carriers being phenotypically normal. The study demonstrated OGM's capability to reveal significant structural aberrations overlooked by traditional methods, improving prenatal diagnosis and genetic counseling, highlighting its potential for high-risk pregnancies.

Bionano Genomics (BNGO) announced its participation in the Spanish Society of Hematology (SEHH) 2022 Conference, taking place from October 6-8 in Barcelona. The company featured six scientific presentations showcasing the applications of its optical genome mapping (OGM) technology in hematologic malignancies like leukemias and lymphomas. These independent studies emphasize OGM's utility in cancer genomics and cytogenetic diagnosis, potentially positioning it as a vital tool for future cancer research.

Bionano Genomics (BNGO) announced a study revealing the efficacy of optical genome mapping (OGM) in investigating hepatocellular carcinoma (HCC). Published in Cancer Research, the research demonstrated OGM's capability to detect replication stress-induced structural variations (SVs) more effectively than whole genome sequencing (WGS). The study found that OGM identified 1.4 times more SVs than WGS, illustrating its potential in understanding oncogenesis mechanisms. CEO Erik Holmlin highlighted OGM's sensitivity for large SV detection, emphasizing its complementary role alongside WGS.

Bionano Laboratories and OptraHEALTH have announced a collaboration to integrate the HealthFAX AI platform to enhance genetic counseling services. This initiative aims to improve patient care by automating educational workflows and providing tailored information on genetic testing. The partnership is expected to increase efficiency and scale operations, allowing Bionano Laboratories to better serve patients seeking genetic diagnostics. Both companies emphasize the importance of reducing anxiety for families awaiting genetic test results through improved access to information and support.

Bionano Genomics (Nasdaq: BNGO) announced the launch of Bionano Laboratories, merging optical genome mapping (OGM) data services with Lineagen's clinical testing services. The newly CLIA-certified lab aims to develop laboratory developed tests (LDTs), starting with a test for facioscapulohumeral muscular dystrophy (FSHD), a key condition in muscular disorder evaluations. This milestone is expected to enhance diagnostic capabilities and facilitate insurance reimbursements for OGM-based assays, aligning with the company's growth strategy.

Bionano Genomics announced a study demonstrating the efficacy of optical genome mapping (OGM) in detecting cryptic balanced chromosomal rearrangements (BCRs) in individuals with recurrent pregnancy loss (RPL). The study involved 11 couples, showing that OGM identified all samples with a 100% concordance to traditional methods like FISH. This highlights OGM's potential as a first-line method for clinical genetic testing, improving detection rates for couples at risk for congenital malformations. CEO Erik Holmlin emphasized the study's importance for patients facing infertility.